<DOC>
	<DOCNO>NCT00323804</DOCNO>
	<brief_summary>Patients chronic hepatitis C respond previous antiviral treatment develop liver fibrosis lead cirrhosis . Maintenance low dose pegylated interferon therapy fibrosis currently investigation large multicenter trial . The aim study ass peginterferon alpha2b plus ribavirin efficient peginterferon alpha2b alone . 454 patient randomize 2 arm efficacy assess , 3 year treatment , Metavir liver fibrosis score improvement .</brief_summary>
	<brief_title>Interest Ribavirin Maintenance Treatment Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b Patients With Chronic Hepatitis C Non Responders Previous Antiviral Therapy .</brief_title>
	<detailed_description>Up 45 % patient chronic hepatitis C respond pegylated interferon/ribavirin combination therapy . These patient prone develop liver fibrosis lead cirrhosis complication . Interferon proven efficient liver fibrosis treatment even case virological non response . Maintenance low dose pegylated interferon therapy currently investigation large multicenter trial . The aim study ass wether peginterferon alpha 2 b ( 0.5 µg/kg/week ) plus ribavirin ( 800-1200 mg accord body weight ) efficient peginterferon alpha 2 b alone long term 3 year treatment liver fibrosis . 454 patient , non responder ( VHC RNA positive 24 week treatment absence ≥ 2 log HCV RNA drop 12 week treatment ) previous peginterferon/ribavirin antiviral treatment randomize 2 arm , double-blind masking ribavirin . The efficacy assess Metavir liver fibrosis score improvement pre post therapeutic liver biopsy .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adults 18 With hepatitis C virus infection ( HCV RNA antiHCV antibody serum ) Not responder previous antiviral treatment use interferon plus ribavirin combination With washout treatment least 6 month With active chronic hepatitis C Metavir fibrosis score ≥ 2 Serum ALT level &gt; upper limit laboratory two occasion within 6 month inclusion Accepting undergo liver biopsy end study Negative pregnancy test woman With social security cover Written informed consent History hepatic complication History transplantation History severe seizure History severe psychiatric disorder Drug addiction within last 12 month Associated condition susceptible responsible liver fibrosis Hepatocellular carcinoma Cardiovascular disease unstable treatment Uncontrolled diabetes Retinopathy Thyroid disease unstable treatment Epilepsy and/or central nervous system functional disorder Autoimmune disease Regular alcohol consumption Pregnancy , breastfeed absence contraception Haemoglobin &lt; 12 g/dl platelet &lt; 50000/mm3 Neutrophils &lt; 1200/ mm3 Severe hepatocellular failure ( prothrombin index lower 60 % ) Renal failure ( creatinine clearance lower 50 mL/Mn ) Associated immunosuppressive drug , corticosteroid , antiviral drug ( study one ) Treatment drug likely effect fibrosis Anticonvulsants Inability tolerate interferon</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Maintenance therapy</keyword>
	<keyword>Non-responder patient</keyword>
	<keyword>Ribavirin/peginterferon combination therapy</keyword>
	<keyword>Hepatitis C , Chronic</keyword>
</DOC>